EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSUAMG00000025111
Gene Symbol: KCNH2
2 Cross references
252 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSUAMG00000024996
Gene Symbol: KCNQ2
2 Cross references
248 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSUAMG00000002272
Gene Symbol: KCNQ3
2 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSUAMG00000012932
Gene Symbol: KCNQ5
2 Cross references
278 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSUAMG00000007708
Gene Symbol: PSEN1
2 Cross references
200 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSUAMG00000027975
Gene Symbol: PSEN2
2 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSUAMG00000020696
Gene Symbol: PSENEN
2 Cross references
183 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSUAMG00000000780
Gene Symbol: PGR
2 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSUAMG00000014178
Gene Symbol: PTGDR
2 Cross references
118 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSUAMG00000023427
Gene Symbol: PTGDR2
2 Cross references
206 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSUAMG00000014290
Gene Symbol: PTGER2
2 Cross references
241 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSUAMG00000023130
Gene Symbol: PTGER3
2 Cross references
194 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).